Patricia Inácio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inácio

Cellectar’s CLR 131 Shows Early Promising Survival Outcomes in Phase 1 Trial of Relapsed or Refractory Myeloma

Myeloma patients who received a single dose of the investigational therapy CLR 131 in an ongoing Phase 1 clinical trial have reached a median overall survival of 22 months, according to the drug’s developer, Cellectar Biosciences. Cellectar is a clinical stage biotech developing phospholipid-drug conjugates (PDCs) for use in anti-cancer therapies.

Immunotherapy Helps Myeloma Patients Who Relapse After Stem Cell Transplant, Study Shows

Many patients with blood cancers, such as myeloma, go into remission after receiving a stem-cell transplant. However, there are still many patients (about one-third) who relapse, a condition usually associated with a poor prognosis. Dana-Farber Cancer Institute researchers tested the effects of a new treatment approach using repeated doses of the immunotherapy drug Yervoy (ipilimumab), showing…

One Multiple Myeloma Induction Therapy Stands Out in Test for Transplant-eligible Patients

Results from a clinical trial support the use of a specific combination drug induction therapy over another three-drug treatment in multiple myeloma patients who are eligible for transplants. The study indicates the combination of bortezomib-thalidomide-dexamethasone (VTD) is a better induction therapy than bortezomib-cyclophosphamide-dexamethasone (VCD). VCD was less efficient and was associated…